News
-
-
-
-
-
-
PRESS RELEASE
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
GENFIT announces positive Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented at EASL Congress 2025 by Ipsen, showing significant efficacy and safety profile improvements -
PRESS RELEASE
GENFIT : les données positives de la Phase 2 évaluant elafibranor dans la Cholangite Sclérosante Primitive (PSC) seront présentées en « late breaking » par Ipsen au congrès de l'EASL 2025
GENFIT annonce les résultats positifs de la Phase 2 sur elafibranor dans la Cholangite Sclérosante Primitive (PSC) à l'EASL 2025 -
PRESS RELEASE
Sparta Capital Ltd. Announces Filing of Annual and Interim Financial Statements and Provides a Corporate Update
Sparta Group (TSXV:SAY) announces filing of annual audited financial statements and interim financial statements. The Company provides updates on strategic partnerships, new CEO, and ongoing nanotechnology testing -
PRESS RELEASE
VINCI successfully places a tap issue of non-dilutive convertible bonds for €150 million to be fully assimilated to its €400 million non-dilutive convertible bonds due February 2030
VINCI successfully completes a tap issue of non-dilutive convertible bonds worth €150 million to be assimilated to existing €400 million bonds due 2030 -
PRESS RELEASE
VINCI annonce le succès du placement complémentaire d’obligations convertibles non-dilutives d’un montant de 150 millions d’euros assimilables aux obligations convertibles non-dilutives d’un montant nominal de 400 millions d’euros à éch
VINCI annonce le succès du placement de 150 millions d’euros en obligations convertibles non-dilutives. Les fonds sont destinés aux besoins généraux de l'entreprise et à l'achat d'options d'achat sur ses propres actions
